EGFR-AKT-mTOR activation mediates epiregulin-induced pleiotropic functions in cultured osteoblasts

Molecular and Cellular Biochemistry

Volumn 398, Issue 1-2, 2015, Pages 105-113

  Fan, Jian bo ^a   Liu, Wei ^a   Zhu, Xin hui ^a   Yuan, Kun ^a   Xu, Da wei ^a   Chen, Jia jia ^a   Cui, Zhi ming ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

AKT mTOR signalings; EGFR; Epiregulin; Osteoblasts

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ALKALINE PHOSPHATASE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; LINSIDOMINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; CARRIER PROTEIN; EGFR PROTEIN, MOUSE; ENZYME INHIBITOR; MTOR PROTEIN, MOUSE; PROTEIN KINASE B; QUINAZOLINE DERIVATIVE; STRESS-ACTIVATED PROTEIN KINASE-INTERACTING PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE; TYRPHOSTIN;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; NONHUMAN; OSTEOBLAST; PLEIOTROPY; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL DEATH; CELL LINE; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; METABOLISM; MOUSE; NEWBORN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

MAMMALIA;

ALKALINE PHOSPHATASE; ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CARRIER PROTEINS; CELL DEATH; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DEXAMETHASONE; ENZYME ACTIVATION; ENZYME INHIBITORS; EPIREGULIN; MAP KINASE SIGNALING SYSTEM; MICE; OSTEOBLASTS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; TOR SERINE-THREONINE KINASES; TYRPHOSTINS;

EID: 84919717253     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-2210-4     Document Type: Article

References (32)

1. Schneider MR, Sibilia M, Erben RG (2009) The EGFR network in bone biology and pathology. Trends Endocrinol Metab 20:517–524
2. Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 1:0010
3. Yarden Y, Shilo BZ (2007) SnapShot: eGFR signaling pathway. Cell 131:1018
4. Herbst RS (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59:21–26
5. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15–31
6. Ng KW, Partridge NC, Niall M, Martin TJ (1983) Stimulation of DNA synthesis by epidermal growth factor in osteoblast-like cells. Calcif Tissue Int 35:624–628
7. Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L (2007) EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem 282:26656–26664
8. Fang MA, Kujubu DA, Hahn TJ (1992) The effects of prostaglandin E2, parathyroid hormone, and epidermal growth factor on mitogenesis, signaling, and primary response genes in UMR 106-01 osteoblast-like cells. Endocrinology 131:2113–2119
9. Barling PM, Lai AK, Nicholson LF (2005) Distribution of EGF and its receptor in growing red deer antler. Cell Biol Int 29:229–236
10. Fan JB, Liu W, Yuan K, Zhu XH, Xu DW, Chen JJ, Cui ZM (2014) EGFR trans-activation mediates pleiotrophin-induced activation of Akt and Erk in cultured osteoblasts. Biochem Biophys Res Commun 447:425–430
11. Canalis E, Raisz LG (1979) Effect of epidermal growth factor on bone formation in vitro. Endocrinology 104:862–869
12. Kumegawa M, Hiramatsu M, Hatakeyama K, Yajima T, Kodama H, Osaki T, Kurisu K (1983) Effects of epidermal growth factor on osteoblastic cells in vitro. Calcif Tissue Int 35:542–548
13. Qin L, Tamasi J, Raggatt L, Li X, Feyen JH, Lee DC, Dicicco-Bloom E, Partridge NC (2005) Amphiregulin is a novel growth factor involved in normal bone development and in the cellular response to parathyroid hormone stimulation. J Biol Chem 280:3974–3981
14. Sibilia M, Wagner B, Hoebertz A, Elliott C, Marino S, Jochum W, Wagner EF (2003) Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart. Development 130:4515–4525
15. Riese DJ 2nd, Cullum RL (2014) Epiregulin: roles in normal physiology and cancer. Semin Cell Dev Biol 28C:49–56
16. Komurasaki T, Toyoda H, Uchida D, Morimoto S (1997) Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. Oncogene 15:2841–2848
17. Makino C, Sano Y, Shinagawa T, Millar JB, Ishii S (2006) Sin1 binds to both ATF-2 and p38 and enhances ATF-2-dependent transcription in an SAPK signaling pathway. Genes Cells 11:1239–1251
18. Cameron AJ, Linch MD, Saurin AT, Escribano C, Parker PJ (2011) mTORC2 targets AGC kinases through Sin1-dependent recruitment. Biochem J 439:287–297
19. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149:274–293
20. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9–22
21. Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6:729–734
22. Gills JJ, Dennis PA (2009) Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 11:102–110
23. Zhou HY, Huang SL (2012) Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer 31:8–18
24. Yang Q, Inoki K, Ikenoue T, Guan KL (2006) Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 20:2820–2832
25. Loza J, Carpio L, Lawless G, Marzec N, Dziak R (1995) Role of extracellular calcium influx in EGF-induced osteoblastic cell proliferation. Bone 16:341S–347S
26. Chandra A, Lan S, Zhu J, Siclari VA, Qin L (2013) Epidermal growth factor receptor (EGFR) signaling promotes proliferation and survival in osteoprogenitors by increasing early growth response 2 (EGR2) expression. J Biol Chem 288:20488–20498
27. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A (2005) Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 4:1533–1540
28. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500–1508
29. Schacke H, Docke WD, Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96:23–43
30. den Uyl D, Bultink IE, Lems WF (2011) Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 13:233–240
31. Weinstein RS (2011) Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 365:62–70
32. Kerachian MA, Seguin C, Harvey EJ (2009) Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol 114:121–128